NDLI: Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Content Provider	Springer Nature : BioMed Central
Author	Purmonen, Timo Puolakka, Kari Bhattacharyya, Devarshi Jain, Minal Martikainen, Janne
Abstract	Objective To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. Methods In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments etanercept and its biosimilar, certolizumab pegol, adalimumab and its biosimilar, golimumab, ustekinumab, intravenous (IV) treatment infliximab, as well as oral non-biologic apremilast. Patients without prior exposure (naïve) to biologics and without moderate to severe psoriasis were considered for secukinumab 150 mg group. Secukinumab 300 mg group included naïve patients with moderate to severe psoriasis and all patients with prior biologic exposure. The PsA Response Criteria (PsARC) at 12-week was primary criteria for treatment response. Other clinical as well as cost related model inputs were derived from relevant clinical trials as well as Finnish publications. The key model outcomes were quality-adjusted life years and incremental cost-effectiveness ratio. An annual 3% discount rate was applied to all future costs and benefits. Model input variations were assessed through sensitivity analyses and alternative scenario analyses. Results For a lifetime horizon (60 years), secukinumab 150 mg dominated all branded SC biologics and apremilast with highest QALY of 8.01 and lowest lifetime cost of €187,776, while it was cost-effective against IV infliximab among biologic-naïve patients without moderate to severe psoriasis. Secukinumab 300 mg was cost-effective against all branded SC biologics and apremilast and dominated IV infliximab among biologic-naïve patients with moderate to severe psoriasis, while it was cost-effective in biologic experienced patients. With the one-way sensitivity analysis, PsARC response, drug acquisition cost, and health assessment questionnaire score were the most important parameters affecting the outcomes. Across all treatment groups, patients on secukinumab were most likely to achieve highest net monetary benefit than other competitors in probabilistic sensitivity analysis. With alternative scenario analysis, results largely remained unchanged. Conclusions Secukinumab is a cost-effective treatment for PsA patients from a Finnish payer’s perspective.
Related Links	https://resource-allocation.biomedcentral.com/counter/pdf/10.1186/s12962-018-0162-3.pdf
Ending Page	10
Page Count	10
Starting Page	1
File Format	HTM / HTML
ISSN	14787547
DOI	10.1186/s12962-018-0162-3
Journal	Cost Effectiveness and Resource Allocation
Issue Number	1
Volume Number	16
Language	English
Publisher	BioMed Central
Publisher Date	2018-11-16
Access Restriction	Open
Subject Keyword	Pharmacoeconomics and Health Outcomes Health Economics Health Administration Quality of Life Research Public Health Health Services Research Psoriatic arthritis Cost-effectiveness Biologics Secukinumab Incremental cost effectiveness ratio Quality adjusted life years
Content Type	Text
Resource Type	Article
Subject	Health Policy
Journal Impact Factor	1.7/2023
5-Year Journal Impact Factor	2.1/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

Calculating disability-adjusted-life-years lost (DALYs) in discrete-time

Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia

Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab

Cost effectiveness of pre-referral antimalarial treatment in severe malaria among children in sub-Saharan Africa

Some reflections on the use of inappropriate comparators in CEA

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Similar Documents

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

Calculating disability-adjusted-life-years lost (DALYs) in discrete-time

Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia

Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab

Cost effectiveness of pre-referral antimalarial treatment in severe malaria among children in sub-Saharan Africa

Some reflections on the use of inappropriate comparators in CEA

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective